Cone-Rod Dystrophy Market Booming At 5.3% CAGR with Leading Players Pfizer Inc. (U.S.), Novartis AG (Switzerland), Abbott Laboratories (U.S.), Sunovion Pharmaceuticals (U.S.) and Cephalon (U.S.)

The Global Cone-Rod Dystrophy Market is expected to grow at a CAGR of approximately 5.3% during the forecast period 2018-2023. The global cone-rod dystrophy market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.

The World Cone-Rod Dystrophy Market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa. The Americas is projected to hold the largest share of the global cone rod dystrophy market due to the increasing eye disorders in the U.S.  According to American Academy of Ophthalmology, over 10 million laser eye surgery procedures are performed in the U.S. each year with a satisfaction rate of 95.4%. Majority of people prefer ophthalmic clinics rather than hospitals. Besides this, increasing number of ophthalmic clinics across the globe has led to increase the market. According to the International Council of Ophthalmology, there are approximately 213,459 ophthalmologists worldwide of which around 19,216 are present in the U.S.

The European region is expected to be the second largest market over the forecast period owing to substantial technological advancements. According to the National Organization for Rare Disorders (NORD), the estimated incidence of the disorder is approximately 1 in 30,000 individuals in the general population. Cone dystrophy is usually present in early infancy or during childhood or early adulthood. However, the disorder has been reported to develop in individuals of all ages including older adults.

The market in the Asia Pacific is expected to witness the fastest growth rate within the forecast period due to increasing geriatric population coupled with rising cases of ocular genetic disorders. The Middle East and Africa are also expected to grow considerably less over the forecast period.

Get Exclusive Sample Copy @ https://www.marketresearchfuture.com/sample_request/5262 .

The World Cone-Rod Dystrophy Market Highlights:

Cone-Rod Dystrophy is a group of related eye disorders that cause gradual loss of vision due to retinal deterioration this may lead to increasing severity or even blindness. Generally, the disorders affects the rod and cones cells present in the retina which are responsible for vision and clarity. According to NCBI, prevalence of cone-rod dystrophies is estimated to be 1 in every 40,000 cases.

According to World Health Organization, in 2014, worldwide 285 million people were estimated to be visually impaired, out of which nearly 246 million have low vision and 39 million are completely blind. Uncorrected errors are the major reasons for causing moderate and severe visual impairment. But still, 80% of the ophthalmic diseases can be cured or prevented by treatment.

There are many new low vision aids, including telescopic and magnifying lenses, providing plenty of choice for users at all stages of sight loss. This technology has also removed many barriers to education and employment. According to American Academy of Ophthalmology, more than 25% of America’s population suffer from minor or major visual complication. More than 150 million Americans use corrective eyewear and spend more than $15 billion each year on eyewear.

Cone-Rod Dystrophy Market Segmentation:

The cone rod dystrophy is segmented on the basis of diagnosis, treatment, and end-users.

On the basis of the diagnosis, the market is segmented into electroretinogram (ERG), clinical history, fundus examination, molecular diagnosis, and others.

On the basis of the treatment, the market is segmented into tinted lenses/ dark sunglass, medications, magnifying devices, and surgery. The medication is classified into vitamin A supplement and anticonvulsant.

On the basis of the end-user, the market is segmented into hospitals, ophthalmic centers, research organizations, and academic institutes.

Cone-Rod Dystrophy Market Key Players:

Some of key the players in the global cone-rod dystrophy market are GlaxoSmithKline Plc. (U.S.), Johnson & Johnson (U.S.), Sanofi (Switzerland), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Abbott Laboratories (U.S.), Sunovion Pharmaceuticals (U.S.), Cephalon (U.S.), DSM (India), Amway (U.S.), Vitamin Shoppe (U.S.), Intas Pharmaceutials Limited (India), Sun Pharmaceuticals Ltd. (India) Emcure Pharmaceuticals Limited (India), Nutrilite (U.S.), NutraScience Labs (U.S.), and others.

Get Discount @ https://www.marketresearchfuture.com/check-discount/5262 .

Major T.O.C Cone-Rod Dystrophy Market:

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

T.O.C Continued……

Ask Questions to Expertise @ https://www.marketresearchfuture.com/enquiry/5262 .

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.